HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody–Drug Conjugate Drug Development in Solid Tumors - KIVIRID

HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody–Drug Conjugate Drug Development in Solid Tumors

Authors: Mark D. Pegram, David Miles, C. Kimberly Tsui, Yu Zong

Published: 2019-10-03

DOI: 10.1158/1078-0432.ccr-18-1976

Source: Full article

Abstract

Abstract